Gilead Sciences Inc (GILD) Dividend History

Gilead Sciences Inc. is a biopharmaceutical company specializing in the development and commercialization of antiviral medicines. Founded in 1987, it is known for its innovative treatments for HIV/AIDS, hepatitis B and C, and other viral infections. Gilead has also expanded into oncology and inflammatory diseases, making significant contributions to advancing global healthcare through its research and development efforts.

333 Lakeside Dr, Foster City, CA, 94404
Phone: (650) 574-3000
Website: https://www.gilead.com

Dividend Yield: 2.79%

Dividend Frequency: Quarterly

Dividend History

Pay Date	Amount	Ex Dividend Date	Record Date
June 27, 2025	$0.79	06/13/2025	06/13/2025
March 28, 2025	$0.79	03/14/2025	03/14/2025
December 30, 2024	$0.77	12/13/2024	12/13/2024
September 27, 2024	$0.77	09/13/2024	09/13/2024
June 27, 2024	$0.77	06/14/2024	06/14/2024
March 28, 2024	$0.77	03/14/2024	03/15/2024
December 28, 2023	$0.75	12/14/2023	12/15/2023
September 28, 2023	$0.75	09/14/2023	09/15/2023
June 29, 2023	$0.75	06/14/2023	06/15/2023
March 30, 2023	$0.75	03/14/2023	03/15/2023
December 29, 2022	$0.73	12/14/2022	12/15/2022
September 29, 2022	$0.73	09/14/2022	09/15/2022
June 29, 2022	$0.73	06/14/2022	06/15/2022
March 30, 2022	$0.73	03/14/2022	03/15/2022
December 30, 2021	$0.71	12/14/2021	12/15/2021
September 29, 2021	$0.71	09/14/2021	09/15/2021
June 29, 2021	$0.71	06/14/2021	06/15/2021
March 30, 2021	$0.71	03/12/2021	03/15/2021
December 30, 2020	$0.68	12/14/2020	12/15/2020
September 29, 2020	$0.68	09/14/2020	09/15/2020
June 29, 2020	$0.68	06/11/2020	06/12/2020
March 30, 2020	$0.68	03/12/2020	03/13/2020
December 30, 2019	$0.63	12/12/2019	12/13/2019
September 27, 2019	$0.63	09/12/2019	09/13/2019
June 27, 2019	$0.63	06/13/2019	06/14/2019
March 28, 2019	$0.63	03/14/2019	03/15/2019
December 28, 2018	$0.57	12/13/2018	12/14/2018
September 27, 2018	$0.57	09/13/2018	09/14/2018
June 28, 2018	$0.57	06/14/2018	06/15/2018
March 29, 2018	$0.57	03/15/2018	03/16/2018
December 28, 2017	$0.52	12/14/2017	12/15/2017
September 28, 2017	$0.52	09/14/2017	09/15/2017
June 29, 2017	$0.52	06/14/2017	06/16/2017
March 30, 2017	$0.52	03/14/2017	03/16/2017
December 29, 2016	$0.47	12/13/2016	12/15/2016
September 29, 2016	$0.47	09/14/2016	09/16/2016
June 29, 2016	$0.47	06/14/2016	06/16/2016
March 30, 2016	$0.43	03/14/2016	03/16/2016
December 30, 2015	$0.43	12/14/2015	12/16/2015
September 29, 2015	$0.43	09/14/2015	09/16/2015
June 29, 2015	$0.43	06/12/2015	06/16/2015

Dividends Summary

Gilead Sciences Inc has issued 41 dividend payments over the past 10 years
The most recent dividend was paid 8 days ago, on June 27, 2025
The first recorded dividend was paid on June 29, 2015
The highest dividend payout was $0.79 per share
The average dividend over this 10 year span is $0.64 per share
Gilead Sciences Inc has increased its dividend payments by 83.72% since 2015

Company News

Why Gilead Scinces Stock Tumbled on Tuesday

The FDA ordered Gilead Sciences to pause its trials of a two-drug HIV treatment combination due to concerns about low CD4+ T-cell levels in some participants. However, the company has numerous other HIV treatments in development, so this setback is not seen as a major issue.

The Motley Fool
2 Stocks, 100%+ Combined Gains - All From Spotting Mispricing Before the Crowd

The article highlights how Investing.com's Fair Value tool helped identify undervalued stocks like Banco Santander and Gilead Sciences, which went on to deliver significant gains by exceeding their projected upside.

Investing.com
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Nurix Therapeutics will host a webcast conference call to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association Congress.

GlobeNewswire Inc.

Featured Companies: NRIX PFE
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer

Gilead's Trodelvy combined with Merck's Keytruda significantly improved progression-free survival in patients with metastatic triple-negative breast cancer compared to Keytruda and chemotherapy.

Benzinga

Featured Companies: MRK
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $69.61, moving -1.58% from the previous trading session.

Zacks Investment Research

Page data last updated 07/04/2025 10:43:35 UTC Dividend yield is calculated using only dividends that have already been paid. Future or declared dividends are not included

Gilead Sciences Inc (GILD) Dividend History

Dividend History

Dividends Summary

Company News

Related Companies